Biological Age is No Barrier for Adult Patients Undergoing CAR T for Non-Hodgkin's Lymphoma or Multiple Myeloma

The recent introduction of chimeric antigen receptor T cell therapy (CAR T) into clinical practice has radically shifted the treatment paradigm of relapse/refractory B-cell non-Hodgkin lymphoma (NHL) and multiple myeloma (MM) .1 The current commercially available products including axicabtagene ciloleucel (axi-cel) ,2 tisagenlecleucel (tisa-cel) ,3 and lisocabtagene maraleucel (liso-cel) 4,5 for NHL and idcabtagene vicleucel (ide-cel) 6,7 and ciltacabtagene autoleucel f d(cilta-cel) 8 for MM have shown impressive response rates and survival outcomes in heavily pretreated patients who would otherwise have very limited treatment options and dismal prognosis.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Tags: The Bottom Line Source Type: research